Tenofovir Monograph

Introduction

Tenofovir is a nucleotide reverse‑transcriptase inhibitor (NRTI) that has become a cornerstone in the treatment of human immunodeficiency virus (HIV) infection and chronic hepatitis B virus (HBV) disease. Originally developed in the 1990s, the drug has undergone several iterations, including the prodrug tenofovir disoproxil fumarate (TDF) and the newer tenofovir alafenamide (TAF), which offer improved pharmacokinetic profiles and reduced renal toxicity. The emergence of tenofovir has been pivotal in the evolution of antiretroviral therapy (ART), contributing to significant reductions in morbidity and mortality worldwide.

For medical and pharmacy students, a thorough understanding of tenofovir’s pharmacodynamics, pharmacokinetics, clinical applications, and potential adverse effects is essential. Mastery of this knowledge supports evidence‑based prescribing, patient counseling, and the management of drug‑related complications.

Learning Objectives

• Explain the chemical structure and mechanism of action of tenofovir and its prodrugs.
• Describe the absorption, distribution, metabolism, and excretion characteristics of tenofovir.
• Identify key clinical indications, dosing regimens, and drug interactions.
• Discuss safety considerations, especially renal and bone toxicity, and monitoring strategies.
• Apply pharmacologic principles to case scenarios involving HIV and HBV treatment.

Fundamental Principles

Core Concepts and Definitions

Tenofovir is a synthetic analogue of adenosine monophosphate (AMP) that mimics the natural nucleoside substrate of reverse transcriptase (RT). Upon phosphorylation to its active diphosphate form, tenofovir competes with deoxyadenosine triphosphate (dATP) for incorporation into viral DNA. Incorporation results in chain termination due to the absence of a 3′‑hydroxyl group, thereby inhibiting further elongation of the viral genome.

The prodrugs TDF and TAF are designed to enhance oral bioavailability. TDF undergoes rapid hydrolysis in the bloodstream to release tenofovir, while TAF remains stable until it enters hepatocytes or lymphocytes, where intracellular enzymes convert it into tenofovir. This differential activation underlies the distinct safety profiles of the two formulations.

Theoretical Foundations

The antiviral activity of tenofovir is governed by kinetic principles that involve the interplay between the drug’s concentration at the site of action, the rate of phosphorylation, and the intrinsic activity of reverse transcriptase. The relationship can be expressed as:

C(t) = C₀ × e^-kt

where C(t) represents the plasma concentration at time t, C₀ is the initial concentration, and k is the elimination rate constant. The area under the concentration‑time curve (AUC) is directly related to the drug’s exposure:

AUC = Dose ÷ Clearance

Renal clearance of tenofovir is largely mediated by glomerular filtration and active tubular secretion, involving transporters such as organic anion transporters (OAT1, OAT3) and multidrug resistance–associated protein 4 (MRP4). Consequently, any alteration in transporter activity, renal function, or concomitant medications may influence tenofovir pharmacokinetics.

Key Terminology

• Reverse Transcriptase Inhibitor (RTI) – A class of antiretroviral drugs that blocks the reverse transcription of viral RNA into DNA.
• Chain Termination – The cessation of DNA elongation due to the incorporation of a nucleotide analog lacking a necessary functional group.
• Prodrug – An inactive or less active compound that is metabolized in vivo to produce an active drug.
• Pharmacokinetic Parameters – Variables such as C_max (maximum concentration), T_max (time to C_max), t_1/2 (elimination half‑life), and clearance.
• Transporters – Membrane proteins facilitating drug movement across cellular membranes; OAT1, OAT3, and MRP4 are particularly relevant for tenofovir.

Detailed Explanation

Pharmacodynamics

Tenofovir’s antiviral efficacy is quantifiable through its inhibitory concentration (IC₅₀) against HIV-1 reverse transcriptase, typically ranging from 12–25 ng/mL in vitro. The drug demonstrates a high barrier to resistance, with most clinically relevant mutations conferring resistance to other NRTIs (e.g., zidovudine, lamivudine) showing little impact on tenofovir susceptibility. However, the K65R mutation can reduce susceptibility, underscoring the importance of resistance testing in treatment failure scenarios.

Pharmacokinetics

Absorption

TDF is absorbed in the small intestine with a relative oral bioavailability of approximately 25%. Food intake increases C_max by 20–30% but does not significantly alter AUC. TAF exhibits markedly higher bioavailability (>70%) due to its stability in plasma and selective cellular uptake.

Distribution

Once in circulation, tenofovir distributes extensively into tissues, with a volume of distribution (V_d) of about 20 L/kg for TDF. The drug’s lipophilicity is low, limiting penetration into the central nervous system (CNS). In contrast, TAF achieves higher intracellular concentrations in hepatocytes and peripheral blood mononuclear cells (PBMCs), enabling effective antiviral activity at lower plasma levels.

Metabolism

Tenofovir itself is not extensively metabolized; however, its prodrugs undergo enzymatic cleavage. TDF is hydrolyzed by nonspecific esterases to release tenofovir, whereas TAF is dephosphorylated by cathepsin A and phosphatases within target cells. The primary metabolic pathway involves phosphorylation to the active diphosphate form, catalyzed by deoxynucleoside kinase (DNK) and ribonucleotide reductase.

Excretion

Renal excretion accounts for the majority of tenofovir elimination. Approximately 90% of the drug is cleared via glomerular filtration and active secretion. The involvement of OAT1, OAT3, and MRP4 suggests that inhibitors of these transporters (e.g., probenecid, cimetidine) can elevate plasma concentrations and increase the risk of toxicity. The elimination half-life (t_1/2) is around 17–18 hours for TDF and 18–20 hours for TAF, supporting once‑daily dosing.

Mathematical Models

The relationship between dose, clearance, and plasma concentration can be represented by the equation: C_ss = (Dose ÷ τ) ÷ Clearance, where C_ss is the steady‑state concentration and τ is the dosing interval. This model assists clinicians in predicting concentration levels in patients with altered renal function or drug interactions.

Factors Affecting Pharmacokinetics

• Renal Function – Declining glomerular filtration rate (GFR) reduces clearance, potentially necessitating dose adjustment or switching to TAF.
• Transporter Polymorphisms – Genetic variations in OAT1, OAT3, or MRP4 can modify drug disposition.
• Drug Interactions – Concomitant use of inhibitors of renal transporters or inducers of hepatic enzymes may influence systemic exposure.
• Age and Body Weight – Elderly patients or those with reduced body mass may exhibit altered distribution and clearance.
• Pregnancy – Physiological changes can increase clearance; however, clinical data suggest standard dosing remains effective.

Safety and Adverse Effects

The most frequently reported adverse events associated with tenofovir therapy include reversible renal tubular dysfunction (manifested as proximal renal tubular acidosis, Fanconi syndrome) and decreases in bone mineral density. These complications are particularly associated with TDF due to higher systemic exposure. TAF, by virtue of lower plasma concentrations and higher intracellular delivery, demonstrates a more favorable renal and skeletal safety profile.

Other potential adverse effects encompass gastrointestinal disturbances (nausea, dyspepsia), mild increases in serum creatinine, and, rarely, hypersensitivity reactions. Monitoring protocols typically involve baseline and periodic assessments of serum creatinine, estimated glomerular filtration rate (eGFR), phosphate levels, and bone mineral density scans where indicated.

Clinical Significance

Relevance to Drug Therapy

Tenofovir’s potency, once‑daily dosing, and high barrier to resistance make it an attractive first‑line agent in combination ART regimens. Its dual activity against HIV and HBV further enhances its utility, particularly in co‑infected patients. The choice between TDF and TAF often hinges upon patient comorbidities, risk of renal impairment, and bone health concerns.

Practical Applications

In HIV management, tenofovir is commonly paired with efavirenz, rilpivirine, or dolutegravir in fixed‑dose combinations, providing simplified regimens that improve adherence. For HBV, tenofovir monotherapy or in combination with pegylated interferon is effective in suppressing viral replication and reducing the risk of cirrhosis and hepatocellular carcinoma.

Clinical Examples

Consider a 48‑year‑old male with newly diagnosed HIV infection and an eGFR of 95 mL/min/1.73 m². Initiation of a tenofovir‑based regimen (e.g., tenofovir alafenamide 25 mg + emtricitabine 200 mg + dolutegravir 50 mg) offers potent viral suppression with minimal renal risk. In contrast, a patient with chronic kidney disease stage 3 (eGFR 45 mL/min/1.73 m²) would benefit from TAF, which preserves renal function while maintaining antiviral efficacy.

Clinical Applications/Examples

Case Scenario 1: HIV Treatment in a Patient with Renal Impairment

A 60‑year‑old female with HIV and chronic kidney disease stage 4 (eGFR 25 mL/min/1.73 m²) is started on a standard tenofovir disoproxil fumarate‑based regimen. Within six weeks, her serum creatinine rises by 0.5 mg/dL, and urinary β‑2 microglobulin levels increase, indicating proximal tubular dysfunction. The clinician switches the patient to tenofovir alafenamide, which reduces systemic exposure and mitigates further renal damage while maintaining viral suppression. Follow‑up demonstrates stable renal function and undetectable viral load.

Case Scenario 2: HBV Co‑infection in an HIV Patient

A 35‑year‑old male presents with HIV and chronic HBV infection. Baseline HBV DNA is 5.2 log₁₀ IU/mL. Tenofovir alafenamide is chosen due its high potency against HBV and lower renal toxicity. The patient’s HBV DNA levels decline below the limit of detection within 12 weeks, and liver function tests normalize. This dual activity underscores tenofovir’s significance in managing co‑infected individuals.

Case Scenario 3: Pregnancy and Tenofovir Use

A 28‑year‑old pregnant woman in her second trimester is diagnosed with HIV. Tenofovir disoproxil fumarate 300 mg daily is prescribed as part of a triple‑drug regimen. Serial monitoring of creatinine and eGFR reveals no significant changes. Post‑partum follow‑up confirms sustained viral suppression, and no adverse fetal outcomes are observed. This case illustrates the safety profile of tenofovir during pregnancy when appropriately monitored.

Problem‑Solving Approaches

• Assessal Function Prior to Initiation – Verify eGFR; consider TAF if eGFR <50 mL/min/1.73 m².
• Screen for Drug Interactions – Evaluate concomitant medications that may inhibit OAT1/OAT3 or induce hepatic enzymes.
• Monitor Laboratory Parameters – Baseline and quarterly serum creatinine, phosphate, and bone density scans where indicated.
• Adjust Dosing or Switch Formulations – In cases of rising creatinine or declining eGFR, transition from TDF to TAF or reduce dose accordingly.
• Educate Patients – Emphasize adherence, report symptoms of renal dysfunction (polyuria, edema), and maintain regular follow‑ups.

Summary / Key Points

• Tenofovir is a potent NRTI with activity against HIV and HBV, available as TDF and TAF prodrugs.
• The active diphosphate metabolite competes with dATP, leading to chain termination of viral DNA synthesis.
• Pharmacokinetics are characterized by oral absorption, extensive tissue distribution, minimal metabolism, and predominantly renal excretion.
• Key pharmacokinetic parameters include C_max, t_1/2, AUC, and clearance, which inform dosing strategies.
• Renal dysfunction and bone toxicity are the most significant adverse effects, primarily associated with TDF; TAF mitigates these risks.
• Clinical applications span first‑line ART regimens and HBV therapy, with considerations for patient comorbidities and drug interactions.
• Monitoring protocols involve renal function tests, phosphate levels, and bone mineral density assessment to prevent complications.
• Case examples demonstrate the practical application of tenofovir in diverse clinical contexts, underscoring the importance of individualized therapy.

By integrating pharmacologic principles with clinical decision‑making, healthcare professionals can optimize tenofovir therapy, enhance patient outcomes, and mitigate potential adverse effects.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.